Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 2
1(100.0%)
1Total
Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT03239015Phase 2Unknown

Efficacy and Safety of Precision Therapy in Refractory Tumor

Role: lead

NCT04116918Unknown

Efficacy and Safety of the Combination of Anlotinib and JS001 in EGFR-TKI Resistant T790M-Negative NSCLC

Role: lead

NCT03701607Unknown

Effect of Chemotherapy on PD-L1 in NSCLC

Role: lead

NCT03683407Unknown

Effect of Chemotherapy on TMB in NSCLC

Role: lead

All 4 trials loaded